This review assessed the role of oral atypical antipsychotic drugs in the management of the behavioural and psychological symptoms of dementia. The authors concluded that the limited evidence suggests that there may be improved efficacy and adverse events compared with typical antipsychotics. The few short-term studies identified provided insufficient evidence to support the authors' conclusions.
Results of the review
Five RCTs (1,570 patients) were included in the review.
The trials were all sponsored by the pharmaceutical company manufacturing the drug. All of the trials were of reasonably good quality. Three RCTs used statistical analyses that took account of multiple comparisons.
Risperidone was studied in 4 trials, each of 12 weeks' duration. All three comparisons with placebo found some beneficial effect of risperidone, although not always for the primary outcome. Two RCTs found no significant difference between risperidone and placebo in extrapyramidal effects; the third RCT did not report the statistical significance of the difference. One RCT found that risperidone increased serious adverse effects (including cerebrovascular events) compared with placebo: 17% versus 9%. No difference between risperidone and haloperidol (2 trials) was demonstrated, except for significant improvements with risperidone over haloperidol in the aggressiveness subscales of BEHAVE-AD and CMAI. Both RCTs found increased extrapyramidal symptoms with haloperidol.
Olanzapine at doses of 5 or 10 mg was superior to placebo, as assessed by the NPI-NH based response rate (1 RCT). The RCT found no statistically significant difference between treatments in extrapyramidal effects. Other adverse effects included somnolence and abnormal gait.
Most of the studies had high rates of withdrawal with active treatment and with placebo.
Authors' conclusions
Few RCTS have evaluated the use of atypical drugs for BPSD. The limited evidence suggests that there may be improved efficacy and adverse events compared with typical antipsychotics.
CRD commentary
The review addressed a specific research question, although the participants and outcomes were not well defined. The literature search was appropriate given that drug trials were sought. Attempts were made to locate unpublished studies but, as it was not stated whether any language restrictions were applied, the potential for language bias could not be assessed. Two reviewers independently selected the studies, assessed validity and extracted the data, thus reducing the potential for bias and errors. The quality of the included studies was good and sufficient detail of the primary studies was presented in the review. The narrative synthesis was appropriate given the varied outcome measures used across the small number of included studies.
Overall, the summary of results the authors presented appears reliable, although it must be remembered that the review's findings are based almost entirely on trials with risperidone, evidence from studies is limited and only shortterm outcomes were assessed. Importantly, the authors' conclusions regarding possible improved efficacy of atypical over typical antipsychotic drugs are not supported by the evidence presented in the review.
